

# International Collaborative Ovarian Neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 09/07/2014	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Claire Amos

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
ICON3

## Study information

**Scientific Title**

**Study objectives**

To compare paclitaxel in combination with carboplatin versus a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin) as first-line treatment of patients with advanced ovarian cancer.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Cancer

**Interventions**

1. One group receives paclitaxel in combination with carboplatin
2. The other group receives a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin)

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Paclitaxel, carboplatin, cyclophosphamide, doxorubicin, cisplatin

**Primary outcome(s)**

Survival time - time to progression, quality of life, health economics

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/06/1998

**Eligibility****Key inclusion criteria**

1. Chemotherapy indicated
2. No previous chemotherapy or radiotherapy
3. No contraindication to chemotherapy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Female

**Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

27/03/1995

**Date of final enrolment**

01/06/1998

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

Medical Research Council (MRC) (UK)

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (MRC) (UK)

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	17/08/2002		Yes	No